Trulicity and weight loss
Pro Research Analysisby 
Searched over 200M research papers
Trulicity and Weight Loss: An Overview
Introduction to Trulicity (Dulaglutide) and Obesity Treatment
Obesity is a growing global health concern, influenced by both environmental and genetic factors. Traditional methods of managing obesity, such as diet and physical activity, often fall short, necessitating the introduction of pharmacotherapy. One promising pharmacological agent is dulaglutide, marketed as Trulicity, a GLP-1 analog that has shown significant potential in aiding weight loss1.
Efficacy of Trulicity in Weight Loss
Case Study Insights
A case report highlighted the use of Trulicity in a 49-year-old patient with morbid obesity. The patient had struggled with obesity since childhood, and conventional weight reduction methods were ineffective. Upon switching to Trulicity (1.5 mg / 0.5 mL s.c.) administered once a week, the patient experienced a significant decrease in body weight and an improvement in overall well-being1. This case underscores the potential of Trulicity as an effective treatment for obesity, particularly in patients who have not responded well to other interventions.
Comparative Analysis: Time-Restricted Feeding and Weight Loss
Systematic Review and Meta-Analysis
A systematic review and meta-analysis examined the effects of time-restricted feeding (TRF) on body weight and metabolism. The analysis included 11 studies, comprising both randomized controlled trials and observational studies. The findings revealed that TRF regimens led to greater weight loss compared to unrestricted-time regimens (WMD: -1.07 kg, 95% CI: -1.74 to -0.40; p = 0.002)2. Additionally, TRF was associated with a significant reduction in fasting glucose concentrations (WMD: -1.71 mg/dL, 95% CI: -3.20 to -0.21; p = 0.03)2.
Conclusion
Trulicity (dulaglutide) has demonstrated promising results in promoting weight loss, particularly in patients with morbid obesity who have not achieved satisfactory outcomes with traditional methods. The case report indicates significant weight reduction and improved well-being with Trulicity use1. Additionally, time-restricted feeding has also shown efficacy in weight loss and metabolic improvements, suggesting that combining pharmacotherapy with dietary interventions could enhance overall treatment outcomes2. Further long-term studies are needed to solidify these findings and optimize obesity management strategies.
Sources and full results
Most relevant research papers on this topic
The use of the GLP-1 analog - dulaglutide in the treatment of morbid obesity - case report
Dulaglutide, a GLP-1 analog, significantly decreased body weight and improved patient well-being in a morbid obesity patient.
Case ReportEffects of time-restricted feeding on body weight and metabolism. A systematic review and meta-analysis
Time-restricted feeding regimens show a greater weight-loss and reduced fasting glucose compared to unrestricted meal consumption approaches.
Meta-Analysis
Highly CitedEffects of time-restricted feeding in weight loss, metabolic syndrome and cardiovascular risk in obese women
Time-restricted feeding effectively reduces weight and BMI without affecting metabolic syndrome biomarkers, and may reduce cardiovascular risk in obese middle-aged women.
RCT
Rigorous JournalHighly CitedEffects of 4- and 6-h Time-Restricted Feeding on Weight and Cardiometabolic Health: A Randomized Controlled Trial in Adults with Obesity.
4- and 6-hour time-restricted feeding regimens both induce mild weight reductions and show promise for improving cardiometabolic health in adults with obesity after 8 weeks.
RCT
Very Rigorous JournalHighly CitedTime-restricted feeding’s effect on overweight and obese patients with chronic kidney disease stages 3-4: A prospective non-randomized control pilot study
Time-restricted feeding (TRF) is an effective and safe weight loss method for overweight and obese patients with moderate-to-severe chronic kidney disease stages 3-4, potentially due to changes in body composition and gut microbiota alterations.
RCTEffect of weight loss and exercise therapy on bone metabolism and mass in obese older adults: a one-year randomized controlled trial.
Weight loss combined with exercise decreases hip bone mineral density in obese older adults, but the beneficial effects on physical function may lower the overall risk of falls and fractures.
RCTRigorous JournalHighly CitedInhibition of PTP1B by Trodusquemine (MSI‐1436) Causes Fat‐specific Weight Loss in Diet‐induced Obese Mice
Trodusquemine effectively induces noncachectic fat-specific weight loss and improves insulin and leptin levels in mice with diet-induced obesity.
Non-RCT
Animal StudyVery Rigorous JournalHighly CitedEffects of Time-Restricted Feeding and Ramadan Fasting on Body Weight, Body Composition, Glucose Responses, and Insulin Resistance: A Systematic Review of Randomized Controlled Trials
Time-restricted feeding may lead to moderate weight loss and improved insulin sensitivity in individuals with overweight/obesity, but more long-term, well-designed studies are needed.
Systematic ReviewVery Rigorous JournalEffects of Trp64Arg Mutation in the β3-Adrenergic Receptor Gene on Weight Loss, Body Fat Distribution, Glycemic Control, and Insulin Resistance in Obese Type 2 Diabetic Patients
The Trp64Arg mutation in the 3-adrenergic receptor gene may predict difficulty in losing body weight, lowering waist-to-hip ratio, and improving glycemic control and insulin resistance in obese patients with type 2 diabetes.
Non-RCTHighly CitedInfluence of the Trp64Arg polymorphism in the beta 3 adrenoreceptor gene on insulin resistance, adipocytokine response, and weight loss secondary to lifestyle modification in obese patients.
The beneficial effect of mild weight reduction through a low caloric diet and exercise program is greatest in subjects with a normal homozygote beta 3 adrenoreceptor gene.
Non-RCT